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Nevertheless, since the end of the 1970s, we have seen a significant fall in the death rate from coronary diseases below the age of 64 years. This reduction is due both to a decrease in the number of new cases and to an improvement in survival after acute cardiac illness. 2 When the origin of these falls is examined, it can be seen that the variations in the classic determinants of risk (hypertension, cholesterol, smoking, obesity) explain about 20% of this fall, but that the major modifications in the treatment of the acute phase of the myocardial infarction (thrombolysis, beta-blockers, conversion enzyme inhibitors, aspirin or other anti-platelet drugs) explain more than 40%. 3 In the context of clinical trials, the study of the effectiveness of these drugs shows, for each of them, a comparative 15-20% reduction of the risk of death for coronary patients. New treatments appear on the market regularly, reducing this vascular risk further. So in view of such progress, do we really need pharmacogenomics and pharmacogenetics in cardiology? In other words, what can we now expect from these new disciplines, born with the booming of genomics? Are they only new marketing concepts or useful tools for better therapeutic progress?
Numerous definitions exist, but one could characterise pharmacogenomics as the use of genomics for the discovery of new treatments. Most of the techniques involved in this discipline require methods of differential screening: comparison of a healthy tissue with a diseased one, of a normal cell with a diseased one, of a normal cell with a treated one, or of diseased cells at different phases in the progression of the disease. 4 The ultimate objective of these comparisons is to discover the differentially expressed genes so as to deduce from them the specific pharmacological targets of the pathological process studied. This reasoning is directed by two key factors: the recent development in biotechnology, allowing the simultaneous characterisation of several hundreds, even several thousands of transcripts, and the postulate that the detection of a difference in expression may indicate the causality. This seductive and simplistic vision conflicts with the everyday reality of scientific research. Firstly, the definitions of cardiovascular diseases, which allow the distinction between normal and pathologic, are founded on very heterogeneous clinical and biological bases. Moreover, the multifactorial nature of cardiovascular diseases adds to the complexity of the underlying molecular mechanisms. 5 Secondly, the high throughput transcription analysis techniques are not so well standardised and the studies of reproducibility or, more generally bench marks are rare, which limits the generalisation of the conclusions drawn. Thirdly, the differences observed are often multiple and lead to the isolation of several hundred transcribed sequences, more than half of which code for genes, the functions of which are still unknown. 6 The initial characterisation of these transcripts is necessary for the definition of the newly expected therapeutic targets, and the genomics techniques cannot respond alone to this objective. If pharmacogenomics wants to reach the ambitious objectives it sets itself, it is therefore essential that it integrates techniques of the post-genome, firstly proteomics, and that it opens up swiftly towards physiology and functional exploration. Also, the times required to obtain specific, new, totally original, even revolutionary, molecules, that have been quoted by the start-up companies supported by some large pharmaceutical companies, will be difficult to adhere to.
Pharmacogenetics can be defined as the study of the influence of the genetic variability on the response of patients to treatments. This concept started in the 1950s, when it was realized that genetically determined variation in drug metabolizing enzyme activity may lead to adverse events. 7 The objectives of pharmacogenetics seem a priori more immediate. They are based on the hypothesis that the differences in sensitivity of patients both to the researched effect of a drug and to its adverse impacts can be attributed to the differences in individual genetic susceptibility. This concept, verified repeatedly by pharmacologists through, for example, the correlation between the kinetics of drugs and polymorphisms of the activity of hepatic enzymes, 8 has been generalised by the arrival of genomics. Pharmacogenetics, although historically older, may be now considered as a part of the broad field of pharmacogenomics. 9 Thus, in parallel with the high throughput reasoning developed for pharmacogenomics, the idea has been established that a systematic screening in clinical trials of the genome by the use of genetic polymorphisms supplied by the single nucleotide polymorphism (SNP) data banks, could characterise the responders and the non-responders and identify the patients likely to present adverse effects. 10 This approach, simple in appearance, also conflicts with several classic problems in epidemiology. Firstly, contrary to traditional genetic screening based on family studies, there is a great risk of wrongly concluding to the existence of statistically significant differences (type 1 error) in allele distributions because of the high number of independent statistical tests performed. In fact, it is envisaged that mostly more than a thousand SNPs will be tested in these studies, and will often be more than the number of patients in the trials. Secondly, the information available on the SNPs (allelic frequencies, linkage disequilibrium, degree of heterozygosity) is often reduced, which significantly limits their contribution. Thirdly, the occurrence of adverse effects in clinical studies, although fortunately not very frequent, is an important factor in the acceptance or non acceptance of a new product by the authorities; however, because of this rarity, they will be very difficult to characterise when considering the common allele frequencies of the SNP selected. Finally, where a number of SNPs could be retained, densification and haplotype studies would be necessary, which would also increase the time taken to obtain clinically useful information by these high throughput systematic approaches.
This brief description of the objectives and limitations of the pharmacogenomics and pharmacogenetics of cardiovascular diseases shows that these new scientific disciplines are beginnings and not ends in themselves. They bring together techniques and tools, already known and used for more than 10 years in basic research: epidemiology, genetics, expression study, factorial analysis, sequencing, genotyping etc. The originality of these disciplines stems from the change of scale induced by the arrival
The Pharmacogenomics Journal of the high throughput techniques in molecular biology, which seem to allow a more global and systematic approach to the questions addressed. We have passed from an era founded on 'line fishing' to one founded on 'trawl fishing' and the pharmaceutical industry cannot but keep up with this evolution. Nevertheless, a heavy task further down the line in sifting the product from these miraculous catches of fish remains. In the case of pharmacogenomics, at some point these wide screenings will produce numerous potential targets, the characterisation of each of which will also demand, in the present state of our knowledge, a long study, but their results will benefit scientific research in general. Similarly the interpretation of genetic profiles encountered specifically in the case of the pharmacogenetics studies, involves the same strategies of analysis as studies of gene-environment interactions, 11 the drug being only one environmental factor among others. We are aware today of the difficulties linked to the analysis of these geneenvironment interactions in epidemiology. In these conditions, one senses the main contribution of these essential disciplines of pharmacogenomics and pharmacogenetics to cardiovascular research and progress. Nevertheless, for the moment, does the pharmaceutical industry need these new techniques in its research strategies for new drugs in the field of cardiology? In the long term certainly. This is all the more so because the investments required by these high throughput approaches are great and cannot be ensured by academic organisations alone, except for high scale governmental projects. Further, the information obtained by these studies will prove one day to be essential for everyone and must be easily accessible by the academic sector. Conversely, the physiopathological and post-genomics repercussions induced by the results obtained from these high throughput techniques will have to rely on targeted academic expertise. It is therefore necessary that from now on the private and academic sectors can join together in even strategies which are in the best interest of both parties, without either of the partners seeing in this a cheap, inexhaustible resource of information and innovation. With regard to the short-term results, the interest seems much less obvious. From the publicity of the various startup companies in biotechnology involved in the pharmacogenomics and pharmacogenetics business, the future looks radiant. In the space of 3-5 years, the truth will emerge from the databases, of new drugs replacing the old ones and the market will be inundated with these original molecules, adapted to the genetic profile of every one of us. This vision of the best of all possible medical and therapeutic worlds is perhaps conceivable and certainly useful for fund-raising. However, the methodological and ethical limitations encountered in everyday research will not be resolved by waving a magic wand, no matter how attractive those promises might be. As opposed to the human population, addiction to drugs of abuse is not a great problem in insects, at least as far as we are aware. Nonetheless, the fruit fly, Drosophila melanogaster, has recently shown potential as a model organism for molecular genetic studies of response pathways to several human drugs of abuse, including cocaine, alcohol, and nicotine. [1] [2] [3] These studies are possible since these drugs induce motor behaviors in insects that are strikingly similar to those induced in higher animals. In addition, repeated drug exposures result in plastic changes in responsiveness; tolerance to alcohol, 4 and reverse tolerance, or sensitization, to repeated exposures to cocaine. 1 Sensitization is of interest in that it represents an animal model for a long-lasting behavioral change that appears linked to the long-lasting drug craving in animals and humans, 5 and also has potential links to mental disorders such as schizophrenia.
6 Here we will focus on studies of sensitization in Drosophila, emphasizing an unexpected link between sensitization and the circadian gene family. 11 in vivo expression of either tetanus toxin light chain, a blocker of evoked transmitter release, or inhibitory or stimulatory G proteins, in the dopamine plus serotonin neurons results in alterations in cocaine responsiveness and inhibition of sensitization. These observations show the involvement of dopamine and/or serotonin in Drosophila cocaine responses, and indicate that sensitization either requires active G protein signaling in the presynaptic neurons, or possibly that sensitization can only come about when levels of amine release are in a near-normal range. The directionality of the responses in Drosophila indicate that postsynaptic responses are modulated in a compensatory direction relative to the magnitude of presynaptic release, a homeostatic phenomonon also seen in vertebrates. In addition, a mutant in the regulatory type II subunit of PKA leads to reduced responsiveness to cocaine and the abolition of sensitization. 12 The real strength of the Drosophila model is in the potential for identification of novel pathways that would be much more difficult to uncover in vertebrates. Recent studies have identified two additional pathways required for cocaine sensitization in Drosophila. First, the trace amine tyramine is essential for sensitization, as shown by a mutant line, inactive (iav) , that is defective in sensitization. This line shows reduced tyramine levels, and sensitization can be restored to iav by
